SCHEMBL5725840

SCHEMBL5725840

O=C(Cc1ccc(Cl)cc1)c1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 1.00
NPC1 O15118 5/20 1.00
L3MBTL1 Q9Y468 2/20 0.71
MAPT P10636 3/20 0.70
MAPK1 P28482 2/20 0.59
PIK3CA P42336 2/20 0.59
MEN1 O00255 1/20 0.59
CYP3A4 P08684 1/20 0.59
HPGD P15428 1/20 0.59
KMT2A Q03164 1/20 0.59
CYP1A2 P05177 1/20 0.54
GAA P10253 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C19 P33261 1/20 0.54
GFER P55789 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
GSK3B P49841 2/20 0.53
CA2 P00918 2/20 0.50
CAMK2A Q9UQM7 1/20 0.50
ME2 P23368 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10649146 1.00 RAB9A (1.00) RAB9ANPC1L3MBTL1MAPTMAPK1
SCHEMBL1753283 0.92 RAB9A (0.85) RAB9ANPC1L3MBTL1MAPTMAPK1
SCHEMBL1642242 0.90 NPC1 (0.81) RAB9ANPC1L3MBTL1MAPTMEN1
Parachlorophenol SCHEMBL28159625 0.87 L3MBTL1 (0.80) RAB9ANPC1L3MBTL1MAPTMAPK1
SCHEMBL1393818 0.85 L3MBTL1 (0.76) RAB9ANPC1L3MBTL1MAPTMAPK1
SCHEMBL12835116 0.84 RAB9A (0.72) RAB9ANPC1L3MBTL1MAPTMEN1
SCHEMBL28167868 0.83 L3MBTL1 (0.73) RAB9ANPC1L3MBTL1MAPTMAPK1
SCHEMBL6202445 0.83 RAB9A (0.71) RAB9ANPC1L3MBTL1MAPTMEN1
SCHEMBL6199337 0.83 RAB9A (1.00) RAB9ANPC1L3MBTL1MAPTMEN1
SCHEMBL13256390 0.83 RAB9A (0.71) RAB9ANPC1L3MBTL1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1705169-A2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators Hormos Medical Ltd. (FI) 2006-09-27 EP disclosed
EP-1235776-B1 TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS HORMOS MEDICAL CORP (FI) 2006-02-08 EP disclosed
US-6875775-B2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD (FI) 2005-04-05 US disclosed
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD. 2003-12-04 US disclosed
US-6576645-B1 Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect HORMOS MEDICAL OY LTD (FI) 2003-06-10 US disclosed
EP-1235776-A1 TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS Hormos Medical Corporation (FI) 2002-09-04 EP disclosed
WO-2001036360-A1 TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS HORMOS MEDICAL CORPORATION (FI) 2001-05-25 WO disclosed
US-4464386-A Insecticidal 3-difluoromethoxyphenyl-1-phenylcarbamoyl-2-pyrazolines NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1984-08-07 US disclosed
US-4410732-A INSECTICIDES NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1983-10-18 US disclosed
US-4407813-A Insecticidal pyrazoline derivatives and composition NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1983-10-04 US disclosed
US-4038415-A ENZYME INHIBITORS NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1977-07-26 US disclosed
US-4016223-A Prostaglandin dehydrogenase inhibiting agents NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1977-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators ESR2, ESR1, GPER1 RAB9A 4327/4885NPC1 1166/4885L3MBTL1 2169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.